BiotechTube
iPSirius

iPSirius

Paris, France· Est.
ipsirius.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

iPSirius is an early-stage biotech venture operating in the high-potential cell and gene therapy space from Paris, France. Founded in 2017, the company remains in a stealth or foundational development phase, as evidenced by its 'Coming Soon' website. This lack of public disclosure indicates it is likely a privately held, pre-revenue entity building its technology platform and initial pipeline before seeking broader visibility or partnerships.

Cell & Gene Therapy

Technology Platform

Likely an induced pluripotent stem cell (iPSC) platform for differentiation into therapeutic cell types or disease modeling.

Opportunities

The global iPSC and cell therapy market is large and growing, driven by demand for curative treatments for degenerative diseases.
iPSC technology offers a scalable path to allogeneic, off-the-shelf cell therapies, potentially improving accessibility and reducing costs.
Position in France provides access to a strong academic base and supportive EU regulatory frameworks for advanced therapies.

Risk Factors

Faces significant scientific risks related to tumorigenicity, cell purity, and manufacturing scalability of iPSC-derived products.
As a stealth-mode, pre-revenue company, it is highly dependent on securing external funding in a competitive investment landscape.
The field is crowded with well-capitalized competitors, creating substantial competitive and execution risk.

Competitive Landscape

The iPSC therapy and technology sector is highly competitive, featuring publicly traded leaders like Fate Therapeutics, as well as numerous private companies and large pharma collaborations. Competition exists across multiple fronts: technological innovation in differentiation and gene editing, intellectual property, manufacturing expertise, and clinical execution. iPSirius will need a clear differentiating advantage to succeed.

More companies in Cell & Gene Therapy →More companies in France →